Larsen G L, Alexander J A, Stanford W
Ann Thorac Surg. 1977 Apr;23(4):323-6. doi: 10.1016/s0003-4975(10)64133-1.
Seventy-two patients with Starr-Edwards aortic prostheses of the 2300 series were followed for 1 to 73 months (average, 22 months) without receiving anticoagulants. Nine patients had clinical evidence of an embolic episode (12.5%). One of these patients died, and 5 were left with a significant residual neurological deficit. Two other patients had hemiparesis but recovered fully. Only 1 episode could be considered minor. The reported lower incidence of thromboembolism in patients receiving this prosthesis with adequate anticoagulation has now led us to reverse our previous position and recommend anticoagulation for patients receiving Starr-Edwards aortic prostheses.
对72例植入2300系列斯塔尔-爱德华兹主动脉瓣膜假体的患者进行了1至73个月(平均22个月)的随访,期间未使用抗凝剂。9例患者有栓塞发作的临床证据(12.5%)。其中1例患者死亡,5例遗留明显的神经功能缺损。另外2例患者出现偏瘫,但完全康复。只有1次发作可被视为轻微发作。据报道,接受这种假体且抗凝充分的患者血栓栓塞发生率较低,这使我们改变了之前的立场,建议对接受斯塔尔-爱德华兹主动脉瓣膜假体的患者进行抗凝治疗。